Segall Bryant & Hamill LLC Cuts Stock Holdings in Vaxcyte, Inc. $PCVX

Posted by Stanley Muller on Aug 3rd, 2026

Segall Bryant & Hamill LLC lowered its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 4.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 183,935 shares of the company’s stock after selling 9,488 shares during the quarter. Segall Bryant & Hamill LLC owned 0.13% of Vaxcyte worth $10,688,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Janus Henderson Group PLC boosted its holdings in Vaxcyte by 23.8% during the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after acquiring an additional 3,188,687 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Vaxcyte by 35.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after purchasing an additional 2,981,038 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Vaxcyte by 18.5% in the fourth quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock valued at $275,286,000 after purchasing an additional 933,539 shares during the last quarter. State Street Corp raised its holdings in shares of Vaxcyte by 4.1% in the fourth quarter. State Street Corp now owns 4,980,005 shares of the company’s stock valued at $229,777,000 after purchasing an additional 194,116 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP lifted its position in shares of Vaxcyte by 7.5% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,068,020 shares of the company’s stock valued at $187,698,000 after purchasing an additional 283,265 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on PCVX shares. Zacks Research cut shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $86.00.

View Our Latest Analysis on PCVX

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $54.08 on Monday. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00. The firm has a market cap of $7.81 billion, a PE ratio of -7.86 and a beta of 1.22. The stock has a fifty day moving average price of $53.25 and a 200-day moving average price of $54.95.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the prior year, the firm earned ($1.04) EPS. As a group, equities analysts anticipate that Vaxcyte, Inc. will post -7.91 EPS for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In other news, CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $57.28, for a total transaction of $572,800.00. Following the completion of the transaction, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at $5,979,745.60. This represents a 8.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 22,461 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $52.50, for a total transaction of $1,179,202.50. Following the sale, the chief executive officer owned 474,703 shares of the company’s stock, valued at approximately $24,921,907.50. The trade was a 4.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 91,396 shares of company stock worth $4,975,725 over the last three months. 3.30% of the stock is currently owned by insiders.

Vaxcyte Company Profile

(Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.